Core Viewpoint - The market anticipates Foghorn Therapeutics Inc. (FHTX) to report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended December 2024 [1] Financial Expectations - The consensus EPS estimate for Foghorn Therapeutics is a loss of $0.29 per share, reflecting a year-over-year improvement of +49.1% [3] - Expected revenues for the quarter are $11.72 million, which represents a significant increase of 103.1% compared to the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analysts' assessments [4] - The Most Accurate Estimate for Foghorn Therapeutics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -29.07%, suggesting a bearish outlook from analysts [10] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with a focus on positive readings [7] - A positive Earnings ESP combined with a strong Zacks Rank (1-3) has historically led to a positive surprise nearly 70% of the time [8] Historical Performance - In the last reported quarter, Foghorn Therapeutics was expected to post a loss of $0.42 per share but delivered a loss of $0.31, resulting in a positive surprise of +26.19% [12] - Over the past four quarters, the company has beaten consensus EPS estimates three times [13] Industry Comparison - Another company in the same industry, Wave Life Sciences, is expected to report a loss of $0.17 per share, indicating a year-over-year change of -13.3%, with revenues projected at $29.14 million, up 0.3% from the previous year [17] - Wave Life Sciences has an Earnings ESP of 40.68%, suggesting a higher likelihood of beating the consensus EPS estimate, despite only surpassing EPS estimates once in the last four quarters [18]

Core Insights - Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines aimed at correcting abnormal gene expression to treat serious diseases, particularly in oncology [1][3] - The company will participate in two significant conferences: the B. Riley Securities Precision Oncology and Radiopharma Conference and the TD Cowen 45th Annual Health Care Conference, showcasing its Gene Traffic Control platform and broad pipeline [1][2] Company Overview - Foghorn Therapeutics is engaged in discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system, utilizing its proprietary Gene Traffic Control platform [3] - The company is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system, with multiple product candidates currently in development for oncology [3] Upcoming Events - The company will present at the Synthetic Lethality Panel on February 28, 2025, and at the TD Cowen conference on March 3, 2025, with presentations by President and CEO Adrian Gottschalk [4] - A webcast of the presentations will be available for 90 days on the company's website [2]

Company Overview - YourBio Health is a medical device company focused on revolutionizing blood collection through its Touch-Activated Phlebotomy (TAP®) technology, which is the first push-button blood collection system [10] - The TAP products utilize microneedles for virtually painless blood draws and are applicable in clinical trials, diagnostics, and wellness settings, enabling reliable at-home blood collection [3][10] - YourBio Health was founded by Flagship Pioneering in 2011 and aims to humanize and decentralize the blood collection process [10] Leadership Appointment - Paul Owen has been appointed as the Chief Executive Officer of YourBio Health and CEO-Partner of Flagship Pioneering, bringing over 35 years of corporate leadership and strategic planning experience [1][2][5] - Owen's previous roles include Board Director and President of Oncodea, Managing Partner for Trusted Health Advisors, and leadership positions at imaware™, OneOme, and Mayo Medical Laboratories [2][6][7] - His strategic vision is expected to drive growth and innovation at YourBio Health, particularly in enhancing the blood collection experience for patients and healthcare providers [3][4] Market Potential - There is significant potential in simplifying blood collection to improve disease treatment and prevention, with the company poised to leverage its technology for broader applications in the healthcare industry [4] - Since its commercial launch, TAP devices have been utilized in multiple clinical trials and have facilitated millions of blood collections, indicating strong market acceptance and utility [3] Flagship Pioneering Overview - Flagship Pioneering is a bioplatform innovation company that has created over 100 scientific ventures since its inception in 2000, resulting in more than $60 billion in aggregate value [9] - The company currently manages $14 billion in assets and has a diverse ecosystem of over 40 companies, including notable names like Moderna and Sana Biotechnology [9]

Foghorn Therapeutics Inc. (FHTX) shares ended the last trading session 11.4% higher at $5.29. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.5% gain over the past four weeks.Last month, the company outlined key strategic objectives and several pipeline goals for 2025. The growing optimism related to Foghorn’s product candidates, which are being developed to treat a wide range of cancers, might have driven the r ...

First of its Kind Scientific Collaboration Will Engage Top Research Institutes in Cambridge, UK with Flagship PioneeringFocus on Scaling and Advancing Flagship's Breakthrough Science and Technologies through the Cambridge Life Sciences EcosystemLONDON, Jan. 23, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced an agreement with top life science organisations Cambridge University Health Partners (CUHP) and the Milner Therapeutics Institute (MTI) to collaborate to j ...

Foghorn Therapeutics Inc. (FHTX) has been beaten down lately with too much selling pressure. While the stock has lost 23.1% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum ...

First-in-class oral selective SMARCA2 (BRM) inhibitor, FHD-909 (LY4050784), advancing in Phase 1 trial for SMARCA4 mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target patient population FHD-909 preclinical combination data with pembrolizumab and KRAS inhibitors to be presented at the AACR Annual Meeting (April 25-30, 2025) Selective degradation of ARID1B achieved with expected update in 2025; continued progress of Selective CBP degrader and Selective EP300 degrader Strong balanc ...

Core Viewpoint - Foghorn Therapeutics Inc. (FHTX) has received a Zacks Rank 1 (Strong Buy) upgrade, indicating a positive outlook for its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks rating system is based on the Zacks Consensus Estimate, which reflects EPS estimates from sell-side analysts for the current and following years [2]. - A strong correlation exists between changes in earnings estimates and near-term stock price movements, making the Zacks rating system valuable for investors [3][5]. - For the fiscal year ending December 2024, Foghorn Therapeutics is expected to earn -$1.53 per share, representing a 34.6% change from the previous year [9]. - Over the past three months, the Zacks Consensus Estimate for Foghorn Therapeutics has increased by 41.5% [9]. Investment Implications - The upgrade to Zacks Rank 1 suggests an improvement in Foghorn Therapeutics' underlying business, which is likely to attract buying pressure and increase its stock price [4][6]. - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - Being in the top 5% of Zacks-covered stocks indicates superior earnings estimate revisions, positioning Foghorn Therapeutics as a strong candidate for market-beating returns in the near term [10][11].

Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy threshold not achieved to support continued development by Foghorn alone Company to prioritize investment into proprietary pipeline and Lilly collaboration programs, including the clinical-stage selective SMARCA2 (BRM) inhibitor, FHD-909 (LY4050784) As of September 30, 2024, the Company had $267.4 million i ...

Core Viewpoint - Foghorn Therapeutics Inc. (FHTX) has experienced significant selling pressure, resulting in a 30.2% decline in stock price over the past four weeks, but analysts anticipate improved earnings reports in the near future [1] Group 1: Stock Performance and Technical Analysis - FHTX's stock is currently in oversold territory, with a Relative Strength Index (RSI) reading of 27.37, indicating a potential for price reversal [5][7] - The stock's heavy selling appears to be exhausting itself, suggesting a possible return to equilibrium in supply and demand [5] - The RSI is a momentum oscillator that helps identify oversold conditions, typically when the reading falls below 30 [2][3] Group 2: Earnings Estimates and Analyst Sentiment - Over the last 30 days, the consensus earnings per share (EPS) estimate for FHTX has increased by 5.2%, indicating a positive trend in earnings revisions [7] - FHTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, further supporting the stock's potential for a turnaround [8]